MedTrace Logo

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

NCT00143091 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-03-24

No results posted yet for this study

Summary

A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

CP-316,311

DRUG

Placebo

DRUG

Sertraline

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-04-30

Countries

  • United States
  • Russia
  • Serbia and Montenegro

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143091 on ClinicalTrials.gov